ACS Clinical Research Program rss


ACS Clinical Research Program sessions at Clinical Congress 2019: A recap(0)

February 1, 2020

A summary of the ACS Clinical Research Program sessions at Clinical Congress 2019 is provided.


Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial

The study design and findings of the PRODIGE 24/CCTG PA6 Trial are outlined, which showed improved survival with modified FOLFIRINOX for resected pancreatic cancer patients.

Figure 1. Schema: ALCHEMIST CHEMO-IO

ALCHEMIST trial has potential to improve outcomes after lung cancer resection

The ALCHEMIST CHEMO-IO is a trial for patients with early-stage non-small cell lung cancer (NSCLC) with the potential to change the way patients with resected NSCLC are treated.


Could axillary reverse mapping be useful in reducing surgical comorbidities?

A summary of some of the research that evaluates the role of axillary reverse mapping in cancer patients.


Evolution in the management of desmoid tumors: Challenging the role of upfront surgical resection

Describes the traditional management of desmoid tumors as well as new approaches, including radiation therapy for locally aggressive tumors.

More in this category

« Older Posts   


Bulletin of the American College of Surgeons
633 N. Saint Clair St.
Chicago, IL 60611


Download the Bulletin App

Apple Store
Get it on Google Play
Amazon store